The present systematic review and meta-analysis critically evaluated the current evidence on tau proteins (p-tau181, p-tau217 and p-tau231) as a blood-based biomarker for the early detection of dementia, with particular focus on its concordance with tau PET, which is the current gold standard for in vivo tau assessment. This evidence concerns the gene MAPT and dementia.